Liraglutide (CAS 204656-20-2) – Research Grade is a high-purity chemical compound.

Liraglutide is a lipopeptide that is an analogue of human GLP-1 in which the lysine residue at position 27 is replaced by arginine and a hexadecanoyl group attached to the remaining lysine via a glutamic acid spacer. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has a role as a glucagon-like peptide-1 receptor agonist and a neuroprotective agent. It is a lipopeptide and a polypeptide.

Research Context

Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has gained significant attention in the fields of endocrinology and metabolic research due to its effective role in managing type 2 diabetes and obesity. Commonly known as Victoza or Saxenda, liraglutide mimics the incretin hormone GLP-1, which is involved in glucose metabolism and appetite regulation.

Research Applications

Liraglutide is primarily used in clinical settings for glycemic control in patients with type 2 diabetes. Its applications extend beyond diabetes management; it has also been investigated for weight management in individuals with obesity. Research studies have demonstrated liraglutide's ability to reduce body weight and improve cardiovascular risk factors, making it a subject of interest for obesity-related research and metabolic syndrome management.

Mechanism of Action

The mechanism of action of liraglutide involves stimulating insulin secretion from pancreatic beta cells in response to elevated blood glucose levels while simultaneously inhibiting glucagon release. This dual effect leads to decreased hepatic glucose production and enhances satiety, resulting in reduced food intake. Additionally, liraglutide slows gastric emptying, further contributing to its effects on weight loss and glycemic control.

Solubility and Storage Advice

Liraglutide is soluble in water and is stable under standard storage conditions. It should be stored in a refrigerator (2°C to 8°C) and protected from light. Once in use, it can be kept at room temperature for a limited period, making it convenient for patient administration. Proper storage is crucial to maintain the compound's efficacy and to prevent degradation.

Future Research Directions

Future research on liraglutide is expected to explore its potential in treating other metabolic disorders, including non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases. Ongoing studies may also investigate the long-term effects of liraglutide on weight maintenance and its role in combination therapies for enhanced efficacy. The potential for developing novel GLP-1 receptor agonists inspired by liraglutide suggests an exciting avenue for future pharmacological advancements.